Targeting metabolic and cognitive pathways of the CNS by intranasal insulin administration.
Intranasal administration effectively delivers neuropeptides to the CNS, bypassing the blood-brain barrier and avoiding systemic side effects. Using this route of administration, direct manipulations of central nervous signalling pathways involved in body weight regulation and cognition are possible. Specifically, the subchronic intranasal administration of insulin has been shown to reduce body fat and improve memory function in the absence of adverse peripheral side effects. These results may fuel the future development of therapeutic strategies in disorders such as obesity and Alzheimer's disease that are promoted by dysfunctions of central nervous neuropeptidergic pathways.
Manfred
M
Hallschmid
Christian
C
Benedict
Jan
J
Born
Werner
W
Kern
D000280:Administration, Inhalation; D000818:Animals; D019440:Anti-Obesity Agents / Q000008:administration & dosage*; D001835:Body Weight / Q000187:drug effects; D002490:Central Nervous System / Q000187:drug effects* / Q000378:metabolism; D003071:Cognition / Q000187:drug effects*; D006801:Humans; D007328:Insulin / Q000008:administration & dosage*; D008568:Memory / Q000187:drug effects; D018697:Nootropic Agents / Q000008:administration & dosage*; D015398:Signal Transduction / Q000187:drug effects
D019440:Anti-Obesity Agents; D007328:Insulin; D018697:Nootropic Agents